Portable hypothermic oxygenated machine perfusion for organ preservation in liver transplantation (PILOT™): A randomized, open-label, clinical trial*

Panayotova et al. published a multicenter, randomized, noninferiority trial which sought to compare liver preservation using the LifePort Liver Transporter to the standard of care, static cold storage.  The study included 142 liver transplant procedures from 9 US centers, and compared outcomes such as early allograft dysfunction, L-GrAFT7 score, primary nonfunction, biliary strictures, and non-anastomotic biliary strictures.

They found that:

  • Lower incidence of EAD in HMP-O2
  • Risk of graft failure as predicted by L-GrAFT7 was lower in HMP-O2
  • Lower incidence of PNF in HMP-O2
  • Lower incidence of biliary strictures in HMP-O2
  • Severe non-infectious adverse events were almost 3x more common in SCS

They concluded that HMP-O2 with LifePort Liver Transporter is safe and efficacious for liver graft preservation compared to SCS.

Read the full article here: https://journals.lww.com/hep/abstract/9900/portable_hypothermic_oxygenated_machine_perfusion.678.aspx

Tagged In:

HMP, Liver, Oxygen

The Latest

Check out the most recent posts

Strengthening the Transplant Ecosystem

By Perry Turner, Managing Director, Commercial & Clinical Operations Organ donation and transplantation is an intricate process that extends far beyond operating rooms and hospitals. Successful transplants are carefully coordinated and planned, requiring close...

James, Senior Vice President, Operations and R&D

James, Senior Vice President, Operations and R&D

I recently joined Organ Recovery Systems as Senior Vice President of Operations and R&D, where I am responsible for driving innovation and operational excellence across the organization. I was drawn to ORS by the opportunity to work alongside a talented team...